Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. by Arsenault, Benoit J et al.
UCSF
UC San Francisco Previously Published Works
Title
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes 
mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in 
patients at high cardiovascular risk.
Permalink
https://escholarship.org/uc/item/70j95949
Journal
Journal of clinical lipidology, 12(1)
ISSN
1933-2874
Authors
Arsenault, Benoit J
Petrides, Francine
Tabet, Fatiha
et al.
Publication Date
2018
DOI
10.1016/j.jacl.2017.10.001
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Journal of Clinical Lipidology (2018) 12, 130–136Effect of atorvastatin, cholesterol ester transfer
protein inhibition, and diabetes mellitus on
circulating proprotein subtilisin kexin type 9
and lipoprotein(a) levels in patients at high
cardiovascular riskBenoit J. Arsenault, PhD1, Francine Petrides, PhD1, Fatiha Tabet, PhD1,
Weihang Bao, PhD, G. Kees Hovingh, MD, PhD, S. Matthijs Boekholdt, MD, PhD,
Stephane Ramin-Mangata, BSc, Olivier Meilhac, PhD, David DeMicco, PharmD,
Kerry-Anne Rye, PhD, David D. Waters, MD, John J. P. Kastelein, MD, PhD,
Philip Barter, MD, PhD, Gilles Lambert, PhD*Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Quebec, Canada
(Dr Arsenault); Department of Medicine, Faculty of Medicine, Universite Laval, Quebec, Quebec, Canada (Dr Arsenault);
School of Medical Sciences, The University of New South Wales, Sydney, New South Wales, Australia (Drs Petrides, Tabet,
Rye, and Barter); Pfizer Inc, New York, NY, USA (Drs Bao and DeMicco); Department of Vascular Medicine, Academic
Medical Center, Amsterdam, The Netherlands (Drs Hovingh and Kastelein); Department of Cardiology, Academic
Medical Center, Amsterdam, The Netherlands (Dr Boekholdt); Inserm, UMR 1188 DeTROI, Universite de La Reunion,
Sainte–Clotilde, France (Drs Ramin-Mangata, Meilhac, and Lambert); and Division of Cardiology, University of
California, San Francisco, CA, USA (Dr Waters)KEYWORDS:
Atorvastatin;
Diabetes mellitus;
Lipoprotein(a);
PCSK9;
CETPClinical Trial Registration: NCT001
1 These authors are considered as fi
* Corresponding author. Inserm UMR
Maxime Riviere, 97490 Sainte Clotilde,
1933-2874/ 2017 National Lipid Ass
https://doi.org/10.1016/j.jacl.2017.10.0BACKGROUND: Proprotein subtilisin kexin type 9 (PCSK9) and lipoprotein (a) [Lp(a)] levels are
causative risk factors for coronary heart disease.
OBJECTIVES: The objective of the study was to determine the impact of lipid-lowering treatments
on circulating PCSK9 and Lp(a).
METHODS: We measured PCSK9 and Lp(a) levels in plasma samples from Investigation of Lipid
Level Management to Understand its Impact in Atherosclerotic Events trial patients with coronary
heart disease and/or type II diabetes (T2D) mellitus. Patients received atorvastatin, which was titrated
(10, 20, 40, or 80 mg/d) to achieve low-density lipoprotein cholesterol levels ,100 mg/dL (baseline)
and were subsequently randomized either to atorvastatin 1 torcetrapib, a cholesterol ester transfer pro-
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Arsenault et al Effect of atorvastatin and diabetes mellitus on PCSK9 and Lp(a) 131RESULTS: At baseline, both plasma PCSK9 and Lp(a) were dose-dependently increased with
increasing atorvastatin doses. Compared with patients without T2D, those with T2D had higher
PCSK9 (357 6 123 vs 338 6 115 ng/mL, P 5 .0012) and lower Lp(a) levels (28 6 32 vs
32 6 33 mg/dL, P 5 .0005). Plasma PCSK9 levels significantly increased in patients treated with tor-
cetrapib (113.1 6 125.3 ng/mL [13.7%], P 5 .005), but not in patients treated with placebo
(12.6 6 127.9 ng/mL [10.7%], P 5 .39). Plasma Lp(a) levels significantly decreased in patients
treated with torcetrapib (23.4 6 10.7 mg/dL [211.1%], P , .0001), but not in patients treated with
placebo (10.3 6 9.4 mg/dL [10.1%], P 5 .92).
CONCLUSION: In patients at high cardiovascular disease risk, PCSK9 and Lp(a) are positively and
dose-dependently correlated with atorvastatin dosage, whereas the presence of T2D is associated with
higher PCSK9 but lower Lp(a) levels. Cholesterol ester transfer protein inhibition with torcetrapib
slightly increases PCSK9 levels and decreases Lp(a) levels.
 2017 National Lipid Association. All rights reserved.Introduction
Statin therapy decreases low-density lipoprotein (LDL)
cholesterol levels and thereby reduces cardiovascular dis-
ease (CVD) risk.1 By inhibiting intracellular cholesterol
synthesis, statins increase the expression of the LDL recep-
tor (LDLR), thus promoting an enhanced clearance of LDL
particles. However, statins also increase the expression of
proprotein convertase subtilisin kexin type 9 (PCSK9), a
natural circulating inhibitor of the LDLR.2 PCSK9 binds
to the LDLR and after endocytosis targets the LDLR that
normally recycles back to the cell surface, for lysosomal
degradation. The efficacy of statins in reducing LDL
cholesterol levels appears to be partially offset by a
concomitant rise in PCSK9.3,4 Pharmacologic inhibition
of PCSK9 with monoclonal antibodies lowers circulating
LDL cholesterol further in patients at high CVD risk and
not at LDL cholesterol therapeutic goals despite aggressive
statin treatment.5,6 It is therefore important to determine
whether and to what extent statins dose-dependently in-
crease circulating PCSK9 levels in such patients.
In contrast to statins, anti-PCSK9 monoclonal antibodies
promote an unexplained 25% to 30% reduction in circu-
lating lipoprotein (a) [Lp(a)] levels.7 Lp(a) is a lipoprotein
subfraction analogous to LDL, where a unique protein ho-
mologous to plasminogen, apolipoprotein (a) [apo(a)], is
covalently tethered to apolipoprotein B100 by a unique di-
sulfide bond.8 Approximately 20% of the Caucasian popu-
lation have high Lp(a) levels (above 50 mg/dL)9 and a
consequent increased risk of coronary heart disease, stroke,
calcific aortic valve stenosis, and heart failure.10–13 The
molecular mechanisms of Lp(a) assembly that likely occurs
at the surface of hepatocytes between a newly synthesized
apo(a) and apoB100 containing lipoproteins (LpB) remain
elusive.14 Apo(a) is never found associated with
triglyceride-rich lipoproteins but rather on cholesterol-rich
LDL particles.15,16 The impact of statin therapy on plasma
Lp(a) levels is somewhat controversial with studies docu-
menting slight decreases in Lp(a) while others suggest
that statins actually increase Lp(a) levels as well as theamount of oxidized phospholipids carried by Lp(a).17
Similar to PCSK9, whether statins dose-dependently influ-
ence Lp(a) plasma levels and whether this could be depen-
dent on metabolic disturbances is unknown.
To shed light on the metabolic states favoring Lp(a)
assembly, and thus elevated Lp(a) levels, in conjunction
with the ongoing development of PCSK9 inhibitors, we
aimed to determine the impact of different doses of statins,
with and without metabolic disturbances of triglyceride-
rich lipoproteins (eg, in type II diabetes [T2D]) and with
and without modulation of their cholesterol content (eg, by
inhibition of the cholesterol ester transfer protein [CETP])
on circulating PCSK9 and Lp(a) levels in patients at high
cardiovascular risk.Methods
Study design
The Investigation of Lipid Level Management to Un-
derstand its Impact in Atherosclerotic Events (ILLUMI-
NATE) trial included 15,067 men and women at high
cardiovascular risk (Trial Registration Number:
NCT00134264). The details of the study population have
been previously described.18 Briefly, men and women
aged 45 to 75 years were eligible if they had a prior history
of myocardial infarction, stroke, acute coronary syndrome,
unstable angina, peripheral vascular disease, or cardiac
revascularization within the period of 30 days to 5 years
before screening. Patients with T2D who met American
Diabetes Association criteria or who were currently on hy-
poglycemic agents were also eligible. During a run-in
period of 4 to 10 weeks, patients received atorvastatin,
which was titrated (if needed) at 2-week intervals to
achieve LDL cholesterol levels ,100 mg/dL with atorvas-
tatin 10, 20, 40, or 80 mg/d. Patients whose LDL choles-
terol level met the target were randomly assigned to
receive either atorvastatin (at a dose established during
the run-in period) plus 60 mg of torcetrapib or atorvastatin
132 Journal of Clinical Lipidology, Vol 12, No 1, February 2018plus placebo. Noteworthy, the use of torcetrapib in ILLU-
MINATE was found to have serious adverse off-target ef-
fects with an increase in cardiovascular events and
related deaths.18 We randomly selected 594 patients
receiving torcetrapib and atorvastatin matched in a 1:2 ra-
tio to 1151 patients receiving placebo and atorvastatin.
This subset of patients was selected to ensure patients
with T2D were overrepresented (48%) and that all atorvas-
tatin doses (10, 20, 40, and 80 mg/d) were also equally
represented.
Laboratory analyses
The level of high-density lipoprotein (HDL) cholesterol
was determined through enzymatic analyses with dextran
sulfate, polyethylene glycol–modified cholesterol esterase,
and cholesterol oxidase, to generate a peroxide that was
measured colorimetrically. Total cholesterol and triglycer-
ide levels were determined by standard enzymatic tech-
niques. LDL cholesterol was quantified by the Friedewald
formula, except when the triglyceride level was above
400 mg/dL, in which case LDL cholesterol levels were
measured by direct beta quantification. Lp(a) was measured
by immunoturbidimetry (Randox, Parramata, Australia)
and PCSK9 measured by enzyme-linked immunosorbent
assay (Cyclex, Nagano, Japan). Homeostasis model assess-
ment of insulin resistance (HOMA-IR) was calculated as
follows: glucose (mg/dL) ! insulin (pmol/L) O
7.175 ! 405.
Statistical analyses
Comparisons of continuous variables were conducted
using the 2-sided Wilcoxon rank-sum test. A chi-square testTable 1 Baseline characteristics of study participants classified on
Atorvastatin and placebo, N 5 115
Male gender, % 83
Diabetes mellitus, % 48
Age, y 62 6 7.5
Total cholesterol, mg/dL 153 6 26
LDL cholesterol, mg/dL 77 6 20
HDL cholesterol, mg/dL 46 6 11
Triglycerides, mg/dL 151 6 75
Apolipoprotein B, mg/dL 72 6 15
Apolipoprotein A-I, mg/dL 123 6 22
Glucose, mg/dL 116 6 36
Insulin, pmol/L 118 6 135
HOMA-IR 5.02 6 8.09
Lipoprotein(a), mg/dL 30 6 33
PCSK9, ng/mL 350 6 120
HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment
convertase subtilisin/kexin type 9.
Data are presented as percentage or mean 6 standard deviation.was used to compare categorical variables. Signed-rank
tests were used to compare baseline and 3-month PCSK9
and Lp(a) levels.Results
Plasma PCSK9 and Lp(a) levels were measured at
baseline (at the end of the run-in period) and 3 months
after randomization in a subset of 594 patients receiving
torcetrapib and atorvastatin and in 1151 patients receiving
placebo and atorvastatin. The characteristics of the study
participants at baseline are presented in Table 1.
At baseline, that is, after the run-in period, both plasma
PCSK9 (Fig. 1) and Lp(a) levels (Fig. 2) were dose-
dependently elevated with increasing atorvastatin doses.
Compared with patients without T2D, those with T2D at
baseline had higher PCSK9 (357 6 123 vs
338 6 115 ng/mL, P 5 .0012) and lower Lp(a) levels
(28 6 32 vs 32 6 33 mg/dL, P 5 .0005). Regardless of
T2D status, higher atorvastatin doses were associated
with higher PCSK9 levels (Fig. 1). Similar to PCSK9
levels, higher atorvastatin doses were associated with
higher Lp(a) levels (Fig. 2). Spearman correlation coeffi-
cients between PCSK9 and Lp(a) levels with parameters
of lipid metabolism and glucose homeostasis are presented
in Table 2. Despite statin therapy, which increases
PCSK93,4 and reduces total and LDL cholesterol levels,
circulating PCSK9 levels were positively associated with
total cholesterol, LDL cholesterol, triglycerides, and apoB
as well as with HDL cholesterol and apoA-I levels, albeit
to a lower extent. Plasma PCSK9 levels were also posi-
tively associated with fasting blood glucose, insulin, and
HOMA-IR. Circulating Lp(a) levels were positivelythe basis of treatment group
1 Atorvastatin and torcetrapib, N 5 594 P value
85 .24
50 .42
62 6 7.6 .75
153 6 27 .99
77 6 21 .79
47 6 12 .49
146 6 78 .02
71 6 16 .06
122 6 22 .06
118 6 41 .95
117 6 109 .88
5.04 6 5.80 .78
31 6 33 .99
340 6 117 .11
of insulin resistance; LDL, low-density lipoprotein; PCSK9, proprotein
Table 2 Spearman correlation coefficients between PCSK9
and lipoprotein(a) levels and parameters of lipid metabolism or
of glucose homeostasis
PCSK9 Lipoprotein(a)
Total cholesterol 0.25 (P , .0001) 0.11 (P , .0001)
LDL cholesterol 0.15 (P , .0001) 0.21 (P , .0001)
HDL cholesterol 0.08 (P 5 .0007) 0.05 (P 5 .03)
Triglycerides 0.16 (P , .0001) 20.11 (P , .0001)
Apolipoprotein B 0.22 (P , .0001) 0.06 (P 5 .01)
Apolipoprotein A-I 0.15 (P , .0001) 0.01 (P 5 .63)
Lipoprotein(a) 0.03 (P 5 .38) –
PCSK9 – 0.03 (P 5 .38)
Glucose 0.14 (P , .0001) 20.05 (P 5 .04)
Insulin 0.17 (P , .0001) 20.05 (P 5 .05)
HOMA-IR 0.18 (P , .0001) 20.06 (P 5 .01)
HDL, high-density lipoprotein; HOMA-IR, homeostasis model
assessment of insulin resistance; LDL, low-density lipoprotein;
PCSK9, proprotein convertase subtilisin/kexin type 9.
Figure 1 Plasma PCSK9 levels at baseline in patients with or
without type II diabetes in the entire study sample and in patients
separated on the basis of atorvastatin dose. *Significantly different
from atorvastatin 10 mg group in patients without type II diabetes.
#Significantly different from atorvastatin 10 mg group in patients
with type II diabetes.
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extent with total cholesterol, apoB, and HDL cholesterol.
There was a weak but significant negative association be-
tween Lp(a) and triglycerides, fasting blood glucose, insu-
lin, and HOMA-IR (Table 2). There was no significant
correlation between PCSK9 and Lp(a) plasma levels.
We also measured PCSK9 and Lp(a) levels after
3 months of treatment either with placebo or with
torcetrapib on top of atorvastatin doses established during
the run-in period. Plasma PCSK9 levels significantly
increased in patients treated with torcetrapib
(113.1 6 125.3 ng/mL [ie, 13.7%], P 5 .005), but not
in patients treated with placebo (12.6 6 127.9 ng/mL
[ie, 10.7%], P 5 .39). Increases in PCSK9 levels with tor-
cetrapib were statistically significant in patients with T2D
only (Fig. 3). In contrast, plasma Lp(a) levels significantly
decreased in patients treated with torcetrapib
(23.4 6 10.7 mg/dL [211.1%], P , .0001), but not in pa-
tients treated with placebo (10.3 6 9.4 mg/dL [11%],
P 5 .92). Decreases in Lp(a) were observed in patients
with and without T2D (Fig. 4). Changes in PCSK9 were
not associated with changes in Lp(a) levels in patients
treated with torcetrapib (Spearman correlation coefficient
r 5 20.03, P 5 .21).Figure 2 Plasma Lp(a) levels at baseline in patients with or
without type II diabetes in the entire study sample and in patients
separated on the basis of atorvastatin dose. *Significantly different
from atorvastatin 10 mg group in patients without type II diabetes.
#Significantly different from atorvastatin 10 mg group in patients
with type II diabetes.Discussion
In this sub-study of ILLUMINATE, a randomized
clinical trial that documented the impact of CETP inhibi-
tion with torcetrapib on cardiovascular outcomes, we found
that atorvastatin therapy was dose-dependently associated
with higher PCSK9 and Lp(a) levels. The presence of T2D
was also associated with higher PCSK9, but lower Lp(a)
levels. We also showed that CETP inhibition with torce-
trapib for 3 months slightly increased PCSK9 levels and
decreased Lp(a) levels.
We found that atorvastatin therapy was dose-
dependently associated with higher PCSK9 levels. It is
well established that all statins significantly increase
circulating PCSK9 levels compared either with placebo or
pretreatment values in humans (as reviewed by SahebkarFigure 3 Changes in plasma PCSK9 levels after 3 months on
placebo or torcetrapib in patients with and without type II dia-
betes. *Significantly different from baseline.
Figure 4 Changes in plasma Lp(a) levels after 3 months on pla-
cebo or torcetrapib in patients with and without type II diabetes.
*Significantly different from baseline.
134 Journal of Clinical Lipidology, Vol 12, No 1, February 2018et al.19). Our study is the largest ever conducted on this
topic and extends the results of a previous study on rosuvas-
tatin4 by comprehensively documenting for the first time a
dose response association between statin and PCSK9 levels.
Compared with patients on 10 mg atorvastatin, those on the
maximal 80 mg atorvastatin treatment dose had 37 ng/mL
higher plasma PCSK9 levels. This increase in PCSK9
levels is of the same magnitude to that reported in patients
on 10 mg atorvastatin vs placebo or pretreatment values
(ie, 140 ng/mL).19 This observation underlines that the ef-
fects of atorvastatin on circulating PCSK9 levels are not
linearly proportional to the treatment dose, similar to
statin-mediated LDL cholesterol–lowering dose effects.20
We also observed in ILLUMINATE that higher atorvas-
tatin doses were associated with elevated Lp(a) levels. The
impact of statin therapy on Lp(a) levels is somewhat
controversial. For instance, in the Aortic Stenosis Progres-
sion Observation: Measuring Effects of Rosuvastatin trial,
40 mg rosuvastatin promoted a 20% increase in circulating
Lp(a) levels.17 In the Treating to New Targets trial, we have
shown that uptitration of atorvastatin doses from 10 to
80 mg/d was associated with a small but significant in-
crease in Lp(a).21 In the Justification for the Use of Statins
in Prevention: an Intervention Trial Evaluating Rosuvasta-
tin trial however, 20 mg rosuvastatin did not significantly
increase Lp(a) levels compared with pretreatment values.22
In contrast, both atorvastatin and simvastatin reduced Lp(a)
in a smaller cohort of heterozygous familial hypercholester-
olemic patients.23 We therefore cannot rule out that ILLU-
MINATE patients requiring higher doses of atorvastatin to
achieve LDL cholesterol ,100 mg/dL were those with
higher untreated baseline Lp(a) levels because assays that
measure LDL cholesterol also include the contribution of
Lp(a) cholesterol.24 In that respect, the single nucleotide
polymorphism rs10455872, that is a strong predictor of
plasma Lp(a) levels, is also the second most importantgenetic determinant of LDL cholesterol lowering with
statins.25
Next, we showed that patients with T2D had higher
PCSK9 levels than patients without T2D, as recently
reported in a smaller cohort.26 However, PCSK9 levels
were not different between patients with vs without T2D
in another smaller study.27 Important questions still remain
regarding the directionality and causality of this associa-
tion. In that respect, insulin has been shown to enhance
PCSK9 expression, which may argue in favor of T2D
causing elevations in PCSK9 levels.28,29 This observation
is also supported by the recent publication of 2 large-
scale genetic associations studies that have shown that
loss-of-function variants at the PCSK9 loci associated
with impaired PCSK9 function may be associated with an
increased risk of T2D.30,31
In contrast, we found that Lp(a) levels were reduced in
patients with T2D compared with patients without T2D.
This result confirms previous studies showing lower Lp(a)
levels in patients with T2D vs patients without T2D and
extends the observations of 3 large prospective studies
demonstrating a strong inverse association of Lp(a) levels
with the risk of incident T2D (as reviewed by Tsimikas8).
However, a genetic study challenged this association by
showing that 4 single nucleotide polymorphism strongly
correlated with the number of apo(a) kringle IV2 repeats
and Lp(a) levels did not predict T2D risk.32 A potential
explanation for reduced Lp(a) levels in patients with T2D
is that insulin reduces apo(a) synthesis in primary hepato-
cytes.33 More likely, because T2D is characterized by
increased levels of triglyceride-rich apoB-containing lipo-
protein, which is (unlike LDL) a poor acceptor for
apo(a), there is probably a reverse causality between
Lp(a) levels and T2D. In line with this hypothesis, Lp(a)
was significantly and negatively correlated with plasma tri-
glycerides in the present study.
We also found that torcetrapib reduced Lp(a) by 11%.
Noteworthy, more potent CETP inhibitors such as anace-
trapib, evacetrapib, and TA-8995 provide 25% to 40%
reductions in Lp(a) levels.34–36 Because CETP inhibition
limits the net flux of triglycerides from triglyceride-rich li-
poproteins to HDL and the net flux of cholesterol esters
from HDL to triglyceride-rich lipoproteins particles, we
speculate that fewer LDL-like particles might serve as sub-
strate for Lp(a) assembly. In that respect, a recent genetic
association study showed that genetic variants at the LPA
locus linked with high Lp(a) levels were causally related
with lower levels of circulating and triglyceride-rich lipo-
proteins particles. The directionality of this association
clearly needs to be clarified.37
Finally, we found that CETP inhibition with torcetrapib
provides a small but significant increase in PCSK9 levels,
in patients with T2D, but not in patients without T2D. The
fact that torcetrapib was found to have serious off-target
effects18 raises the possibility that the effects of torcetrapib
observed in our study may have been unrelated to CETP in-
hibition. In contrast to our findings, other CETP inhibitors
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and monkeys.38–41 Additional research will be needed to
determine whether changes in PCSK9 levels result from a
modulation of the canonical sterol regulatory element-
binding protein 2 transcription factor pathway or from
off-target effects of torcetrapib.
In humans, the impact of CETP inhibition on PCSK9
appears to rely on background lipid-lowering therapy.42 In a
study that included 39 mildly hypercholesterolemic pa-
tients, anacetrapib (100 mg/d) decreased PCSK9 levels by
18% in monotherapy but had no significant influence on
PCSK9 levels (13.4%) on top of atorvastatin 20 mg/d.
Interestingly, plasma PCSK9 levels were weakly but posi-
tively associated with CETP activity in a cross-sectional
study of 450 participants in a high-risk primary prevention
setting.43 Carriers of the PCSK9-R46L loss-of-function
variant (linked with lower LDL cholesterol levels) also pre-
sented with lower CETP activity. This association has not
been replicated in another study.44 Thus, targeting CETP
appears to influence PCSK9. Whether targeting PCSK9
also influences CETP activity will require confirmation.
We conclude that (1) both PCSK9 and Lp(a) levels are
positively and dose-dependently increased by atorvastatin.
The mechanisms by which statins increase PCSK9 levels
are well known,3,4 but those by which higher atorvastatin
doses may increase Lp(a) levels remain elusive. (2) The
presence of T2D is associated with higher PCSK9, but
lower Lp(a) levels. Whereas impaired apoB-containing li-
poprotein remodeling in T2D and on CETP inhibition ap-
pears to be a plausible causative mechanisms for reduced
Lp(a) in those patients, it is not clear as to why patients
with T2D have higher PCSK9 levels and why CETP inhibi-
tion with torcetrapib increased PCSK9 levels in these pa-
tients. The physiological link(s) between glycemic
parameters, PCSK9, LDL receptor function, and Lp(a)
metabolism clearly needs to be addressed in future studies.Acknowledgments
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